Literature DB >> 8680741

Enhancement of the haemodynamic effects of NG-monomethyl-L-arginine by transforming growth factor-beta 1 in conscious, normal, but not endotoxaemic, rats.

S M Gardiner1, P A Kemp, J E March, T Bennett.   

Abstract

1. Male, Long Evans rats (350-450 g) were chronically instrumented for the measurement of regional haemodynamics, and the effects of TGF-beta 1 (25 micrograms kg-1 i.v. bolus) were assessed during infusion of saline (n = 9) or lipopolysaccharide (LPS, 150 micrograms kg-1 h-1; n = 12). In the same animals, responses to NG-monomethyl-L-arginine (L-NMMA 10 mg kg-1 bolus; 10 mg kg-1 h-1 infusion) were determined 18 h after administration of TGF-beta 1. In a separate experiment, the effects of the endothelin antagonist, SB 209670 (10 micrograms kg-1 min-1) on responses to TGF-beta 1 and to L-NMMA subsequently, were determined. 2. In the absence of LPS, TGF-beta 1 had slow-onset bradycardic and pressor effects accompanied by mesenteric and hindquarters, but not renal, vasoconstriction. Eighteen hours after TGF-beta 1, these effects had gone, but the bradycardic, pressor, and mesenteric vasoconstrictor responses to L-NMMA were enhanced. The haemodynamic changes following TGF-beta 1, and the augmentation of the subsequent responses to L-NMMA, were inhibited by SB 209670. These results are consistent with TGF-beta 1 stimulating the synthesis and release of endothelin, and an involvement of the latter in responses to L-NMMA. 3. The pressor effects of TGF-beta 1 were similar in LPS-infused and saline-infused animals, but in the former group the mesenteric vasoconstriction was enhanced and the hindquarters vasoconstriction diminished. Since, in the absence of TGF-beta 1, LPS-infused animals showed a developing hindquarters vasodilatation and mesenteric vasoconstriction, it is feasible that, in the presence of TGF-beta 1 and LPS together, the haemodynamic profile represented an amalgam of the individual effects of the two interventions, rather than a specific effect of TGF-beta 1 on the haemodynamic sequelae of endotoxaemia. 4. In the presence of LPS, haemodynamic responses to L-NMMA were suppressed, and TGF-beta 1 generally did not affect this suppression. A possible explanation of this observation is that LPS increased circulating endothelin levels, and thus resulted in desensitization to the effects of endothelin released following administration of L-NMMA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8680741      PMCID: PMC1909216          DOI: 10.1111/j.1476-5381.1995.tb15961.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Regulation of endothelin-1 synthesis in cultured guinea pig airway epithelial cells by various cytokines.

Authors:  T Endo; Y Uchida; H Matsumoto; N Suzuki; A Nomura; F Hirata; S Hasegawa
Journal:  Biochem Biophys Res Commun       Date:  1992-08-14       Impact factor: 3.575

2.  Cytokine stimulated endothelin release from endothelial cells.

Authors:  S M Kanse; K Takahashi; H C Lam; A Rees; J B Warren; M Porta; P Molinatti; M Ghatei; S R Bloom
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

3.  Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma.

Authors:  A Ding; C F Nathan; J Graycar; R Derynck; D J Stuehr; S Srimal
Journal:  J Immunol       Date:  1990-08-01       Impact factor: 5.422

4.  Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line.

Authors:  K Ohta; Y Hirata; T Imai; K Kanno; T Emori; M Shichiri; F Marumo
Journal:  Biochem Biophys Res Commun       Date:  1990-06-15       Impact factor: 3.575

5.  Mediation of cardioprotection by transforming growth factor-beta.

Authors:  A M Lefer; P Tsao; N Aoki; M A Palladino
Journal:  Science       Date:  1990-07-06       Impact factor: 47.728

6.  The induction of nitric oxide synthase activity is inhibited by TGF-beta 1, PDGFAB and PDGFBB in vascular smooth muscle cells.

Authors:  V B Schini; W Durante; E Elizondo; T Scott-Burden; D C Junquero; A I Schafer; P M Vanhoutte
Journal:  Eur J Pharmacol       Date:  1992-06-17       Impact factor: 4.432

7.  Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion.

Authors:  A M Lefer; X L Ma; A S Weyrich; R Scalia
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

8.  Inhibition of cytokine-induced nitric oxide production by transforming growth factor-beta 1 in human smooth muscle cells.

Authors:  D C Junquero; T Scott-Burden; V B Schini; P M Vanhoutte
Journal:  J Physiol       Date:  1992-08       Impact factor: 5.182

9.  Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells.

Authors:  H Kurihara; M Yoshizumi; T Sugiyama; F Takaku; M Yanagisawa; T Masaki; M Hamaoki; H Kato; Y Yazaki
Journal:  Biochem Biophys Res Commun       Date:  1989-03-31       Impact factor: 3.575

10.  In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670.

Authors:  S A Douglas; R M Edwards; J D Elliott; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more
  1 in total

1.  Selective versus non-selective suppression of nitric oxide synthase on regional hemodynamics in rats with or without LPS-induced endotoxemia.

Authors:  Xing Cheng; Susan W S Leung; Lawrence S Lo; Catherine C Y Pang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-03-04       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.